alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 551–575 of 610 studies · free to read (page 23 of 25) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 610 studies tagged frontotemporal — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Communications Medicine 2025-12-12

Accurate diagnosis of frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominance remains challenging due to lack of clinical characterization, and standardized terminology. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of hypersexuality on spousal carers of patients with Parkinson’s disease and frontotemporal dementia: a qualitative study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. BMJ Open 2025-04-01

The thematic analysis identified 12 themes: manifestations, sexual practices, impact, control, emotional formulations, beliefs in causes of hypersexuality and attributions, relationship with the partner, dealing with hypersexuality, coping with hypersexuality, self-image, stigma and professional help-seeking. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multiplex connectomics reveal altered networks in frontotemporal dementia: A multisite study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Network Neuroscience 2025-01-01

A network neuroscience perspective can significantly advance the understanding of neurodegenerative disorders, particularly frontotemporal dementia (FTD). 5 key findings →

Participants: 28 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Behavioral variant frontotemporal dementia as a model for understanding the cognitive and cerebral determinants of verbal creativity

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Behavioral and Brain Functions 2025-08-23

We dissociated four key cognitive components underlying remote thinking: spontaneous associative thinking, inhibition of unoriginal responses, intentional remote associative thinking, and verbal initiation; and replicated them in three independent datasets. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characterizing the distinct neuroanatomical phenotypes, cognitive profiles, and transcriptomic signatures of brain structural subtypes in Parkinson's disease with mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neurobiology of Disease 2025-10-15

Two distinct subtypes emerged. Subtype 1 (n = 63) features localized supra-normal gray matter volume deviations in dorsolateral prefrontal regions, elevated free water indicating microstructural disruption, executive dysfunction, and transcriptional enrichment in metabolic dysfunction and neurodegenerative pathways. 5 key findings →

Participants: 115 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

An immersive virtual reality shopping task detects declines in instrumental activities of daily living in individuals with Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Parkinsonism & Related Disorders 2024-05-28

There were no between-group differences in traditional performance measures of motor, cognitive, or IADL function. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comparing phenotypic features between Parkinson’s disease dementia and dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Neurology 2026-02-01

Patients with PDD showed a more severe phenotype than those with DLB, with higher scores in motor severity, hallucinations, delusions, somnolence, and urinary dysfunction (all p≤0.01). 5 key findings →

Participants: 31 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Frontotemporal dementia as a consequence of GRN mutations: From disease cause to models to therapies

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Pharmacological Research 2025-09-17

Frontotemporal dementia (FTD) encompasses a broad, clinically and neuropathologically diverse group of neurodegenerative disorders associated with changes in personality, behaviour, and/or language due to the progressive degeneration of the frontal and temporal lobes of the brain. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-04-01

Onset-predictive biomarker tests (OPBTs) for genetic frontotemporal dementia (FTD) may predict symptom onset in coming years. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dopaminergic changes in the subgenual cingulate cortex in dementia with lewy bodies associates with presence of depression

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Translational Psychiatry 2025-03-20

In addition to the core clinical features of fluctuating cognition, visual hallucinations, and parkinsonism, individuals with dementia with Lewy bodies (DLB) frequently experience chronic and debilitating major depression. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comparing clinical features of behavioral variant frontotemporal dementia and Alzheimer's disease using network analysis

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-06-01

= 62.87, SD = 9.46, 36.52% female). Both networks were densely connected, reflecting comorbidity between neuropsychiatric symptoms and cognitive scores. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Frontotemporal dementia patient-derived iPSC neurons show cell pathological hallmarks and evidence for synaptic dysfunction and DNA damage

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Molecular Psychiatry 2025-09-26

Frontotemporal dementia (FTD) is the second most common cause of dementia in patients under 65 years, characterized by diverse clinical symptoms, neuropathologies, and genetic background. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Molecular Neurodegeneration 2025-08-12

Lewy body dementia (LBD) is a neurodegenerative disorder characterized by a combination of progressive dementia and spontaneous parkinsonian symptoms. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Peripheral Single‐Cell Immune Characteristics Contribute to the Diagnosis of Alzheimer's Disease and Dementia With Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 38 out of 100. CNS Neuroscience & Therapeutics 2025-01-01

These models demonstrated high diagnostic efficacy in distinguishing diseased samples from healthy donors as well as distinguishing AD and DLB cases. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of Neuropsychiatric Symptoms on Caregiver Burden of People With Dementia With Lewy Bodies: A Multicentre Prospective Longitudinal Study

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Psychogeriatrics 2025-05-19

At the initial visit, the mean age of individuals with DLB was 80.8 (5.8) years; their mean Mini-Mental State Examination score was 20.6 (5.1). 5 key findings →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Profile of impairments in social and non-social cognition in vascular dementia compared to Alzheimer’s disease and behavioral variant frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of the International Neuropsychological Society 2025-05-01

< .01). All patient groups were also impaired on AVLT encoding, TMT-B and TMT B/A. Social and non-social neurocognitive functions differed between groups, with specific impairments in processing speed in VaD, emotion recognition in bv-FTD and memory retrieval in AD, and memory encoding and cognitive control impaired in all three groups. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuropsychological and clinical indicators of Lewy body and Alzheimer's pathology

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Alzheimer s Disease Reports 2025-01-13

Gait disturbances (odds ratio (OR) = 19.32; p = 0.01), visual-spatial complaints (OR = 6.06; p = 0.03), and visual hallucinations (OR = 31.06; p = 0.002) predicted DLB compared to AD, along with better memory (OR = 3.42; p = 0.003), naming (OR = 3.35; p = 0.002), and worse processing speed (OR = 0.51; p = 0.01). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events